Brivanib
- Generic Name
- Brivanib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C19H19FN4O3
- CAS Number
- 649735-46-6
- Unique Ingredient Identifier
- DDU33B674I
- Background
Brivanib is under investigation for the treatment of HepatoCellular Carcinoma. Brivanib has been investigated for the treatment of Solid Tumors, Hepato Cellular Carcinoma (HCC), and Metastatic Colorectal Cancer (MCRC).
- Associated Conditions
- -
- Associated Therapies
- -
A Study of Niraparib in Combination With Brivanib in Recurrent Ovarian Cancer
- First Posted Date
- 2019-03-29
- Last Posted Date
- 2019-03-29
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 24
- Registration Number
- NCT03895788
- Locations
- 🇨🇳
Jing Wang, Changsha, Hunan, China
Determine the Pharmacokinetics and Safety of Brivanib in Chinese Subjects With Advanced Primary Liver Cancer (Hepatocellular Carcinoma: HCC)
- First Posted Date
- 2012-02-28
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 17
- Registration Number
- NCT01540461
- Locations
- 🇨🇳
Local Institution, Nanjing, Jiangsu, China
Irinotecan Plus Brivanib in Metastatic Colorectal Cancer (CRC) Enriched for Elevated Levels of Plasma FGF
- Conditions
- Interventions
- First Posted Date
- 2011-06-07
- Last Posted Date
- 2020-09-03
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 8
- Registration Number
- NCT01367275
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Comparison of Brivanib and Best Supportive Care (BSC) With Placebo and BSC for Treatment of Liver Cancer in Asian Patients Who Have Failed Sorafenib Treatment
- First Posted Date
- 2010-04-22
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 87
- Registration Number
- NCT01108705
- Locations
- 🇨🇳
Local Institution, Taoyuan, Taiwan
Combination of Brivanib With 5-Fluorouracil/Leucovorin (5FU/LV) and 5-Fluorouracil/Leucovorin/Irinotecan (FOLFIRI)
- Conditions
- Interventions
- First Posted Date
- 2010-01-12
- Last Posted Date
- 2014-09-16
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 49
- Registration Number
- NCT01046864
- Locations
- 🇺🇸
Scott & White Memorial Hospital And Clinic, Temple, Texas, United States
🇺🇸Texas Oncology, Dallas, Texas, United States
🇺🇸Usc/Norris Comprehensive Cancer Center, Los Angeles, California, United States
Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC
- Conditions
- Interventions
- First Posted Date
- 2009-05-27
- Last Posted Date
- 2019-12-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 734
- Registration Number
- NCT00908752
- Locations
- 🇺🇸
The University Of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Sharp Clinical Oncology Research, San Diego, California, United States
🇺🇸Seattle Cancer Care Alliance, Seattle, Washington, United States
First Line Hepato Cellular Carcinoma (HCC)
- Conditions
- Interventions
- First Posted Date
- 2009-03-10
- Last Posted Date
- 2016-10-17
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1714
- Registration Number
- NCT00858871
- Locations
- 🇺🇸
Agajanian Institute Of Hematology And Oncology, Downey, California, United States
🇺🇸Sharp Clinical Oncology Research, San Diego, California, United States
🇺🇸James Graham Brown Cancer Center, Louisville, Kentucky, United States
Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment
- Conditions
- Interventions
- First Posted Date
- 2009-01-21
- Last Posted Date
- 2019-10-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 587
- Registration Number
- NCT00825955
- Locations
- 🇺🇸
Mayo Clinic Arizona, Scottsdale, Arizona, United States
🇺🇸UF Health Clinical Research Center, Gainesville, Florida, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types
- First Posted Date
- 2008-03-12
- Last Posted Date
- 2015-10-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 597
- Registration Number
- NCT00633789
- Locations
- 🇬🇧
Local Institution, Surrey, United Kingdom
🇺🇸Memorial Sloan Kettering Cancer Ctr, New York, New York, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Phase I/II Combination With Irinotecan- Erbitux
- Conditions
- Interventions
- First Posted Date
- 2008-01-16
- Last Posted Date
- 2015-11-04
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 38
- Registration Number
- NCT00594984
- Locations
- 🇺🇸
Usc/Norris Comprehensive Cancer Center Hospital, Los Angeles, California, United States
🇺🇸Usc/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Washington University, Saint Louis, Missouri, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.